The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%. The disease due to the coronavirus 2019 (i.e., COVID-19) is associated with a wide range of clinical symptoms. As the primary site of viral invasion is the upper respiratory airways, lung infection is the most common complication. Most infected patients are asymptomatic or experience mild or moderate form of the disease (80 %). A lower proportion (15%) develop severe pneumonia with variable level of hypoxia that may required hospitalization for oxygen therapy. In the most severe cases (5%), patients evolve towards critical illness with organ failure such as the acute respiratory distress syndrome (ARDS). At this stage, invasive mechanical ventilation is required in almost 70 % and the hospital mortality rises to 37 %. Immune cells are key players during SARS CoV-2 infection and several alterations have been reported including lymphocytes (T, B and NK) and monocytes depletion, and cells exhaustion. Such alterations were much more pronounced in patients with the most severe form of the disease. Beside, a dysregulated proinflammatory response has also been pointed out as a potential mechanism of lung damage. Finally, COVID-19 is associated with an unexpectedly high incidence of thrombosis which probably results from the viral invasion of endothelial cells. The investigators aim to explore prospectively the alterations of innate and adaptive immune cells during both the acute and the recovery phase of SARS CoV-2 pneumonia. Flow and Spectral cytometry will be used to perform deep subset profiling focusing on T, B, NK, NKT, gamma-gelta T, monocytes and dendritic cells. Each specific cell type will be further characterized using markers of activation/inhibition, maturation/differenciation and senescence as well as chemokines receptors. T-cell memory specificity will be explore using specific SARS CoV-2 pentamer. Platelet activation and circulating microparticles will be explore using flow cytometry. Serum SARS CoV-2 antibodies (IgA, IgM, IgG), serum cytokines, and serum biomarkers of alveolar epithelial and endothelial cells will be analyze using ELISA and correlate with the severity of the disease.
Study Type
OBSERVATIONAL
Enrollment
100
Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
Hopital Europeen Marseille
Marseille, France
RECRUITINGHopital Nord
Marseille, France
RECRUITINGProfiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 0
Profiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 7
Profiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 14
Profiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 28
Profiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 90
Profiling of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of cells population using spectral cytometry of PBMCs.
Time frame: Day 180
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 0
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 7
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 14
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 28
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 90
Functional state of innate and adaptive immune cells during SARS CoV-2 infection.
Determination of the functional state of immune cells using spectral cytometry
Time frame: Day 180
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 0
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 7
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 14
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 28
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 90
Serum IgA, IgM and IgG antibodies during SARS CoV-2 infection.
Measurement of serum SARS CoV-2 IgA, IgM and IgG antibodies using Elisa.
Time frame: Day 180
Platelet activation and circulating microparticles assessment during SARS CoV-2 infection.
Determination of platelet activation and circulating microparticles levels using flow cytometry.
Time frame: Day 0
Platelet activation and circulating microparticles assessment during SARS CoV-2 infection.
Determination of platelet activation and circulating microparticles levels using flow cytometry.
Time frame: Day 7
Platelet activation and circulating microparticles assessment during SARS CoV-2 infection.
Determination of platelet activation and circulating microparticles levels using flow cytometry.
Time frame: Day 14
Platelet activation and circulating microparticles assessment during SARS CoV-2 infection.
Determination of platelet activation and circulating microparticles levels using flow cytometry.
Time frame: Day 28
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 0
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 7
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 14
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 28
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 90
Serum concentration of Pro-inflammatory and Anti-inflammatory cytokines in response to SARS CoV-2 infection.
Measurement of IL1β, IL-6, IL-10, IL-17A, IL-18, TNFα, IFNγ, CRTP-6 using Elisa.
Time frame: Day 180
Serum alveolar epithelial and endothelial cells biomarkers during SARS CoV-2 infection.
Measurement of KL-6, CC-16, S-RAGE, ANG-2 using ELISA.
Time frame: Day 0
Serum alveolar epithelial and endothelial cells biomarkers during SARS CoV-2 infection.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measurement of KL-6, CC-16, S-RAGE, ANG-2 using ELISA.
Time frame: Day 7
Serum alveolar epithelial and endothelial cells biomarkers during SARS CoV-2 infection.
Measurement of KL-6, CC-16, S-RAGE, ANG-2 using ELISA.
Time frame: Day 14
Serum alveolar epithelial and endothelial cells biomarkers during SARS CoV-2 infection.
Measurement of KL-6, CC-16, S-RAGE, ANG-2 using ELISA.
Time frame: Day 28
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 0
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 1
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 2
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 3
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 5
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 7
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 9
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 11
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 14
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 17
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 21
Kinetic of surface biomarkers expression on neutrophils (C64) and monocytes (CD169, HLA-DR) during SARS CoV-2 infection.
Measurement of nCD64, mCD169 and mHLA-DR using the VersaPOC one-step rapid flow cytometry method.
Time frame: Day 28